Literature DB >> 1112820

Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin.

J S Rosenberg, D L Beeler, R D Rosenberg.   

Abstract

In this communication we describe the first method for isolating human Factor V. The final product contains no other coagulation components as judged by functional assays and is physically homogeneous as shown by isofocusing gel electrophoresis. In addition, we present a means for obtaining intrinsically activated human Factor X-a. This preparation is usually homogeneous as judged by isofocusing gel electrophoresis. However, on occasion, an additional minor electrophoretic species with Factor X-a activity is observed. Furthermore, we describe the use of isoelectric focusing in sucrose density gradients to free human prothrombin from contamination by coagulation factors and other components. These homogeneous human proteins are employed to examine the conversion of prothrombin to thrombin in the presence and absence of human antithrombin. The latter component is responsible for virtually all of the plasm's capacity to neutralize Factor X-a and thrombin. In the absence of antithrombin, prothrombin (67,800) is converted to the precursor P-2 (51,600) and the fragment F-a (19,500). Subsquently, P-2 is cleaved to form the precursor P-3 (37,000), and the fragment F-b (11,500). Finally, P3 IS proteolyzed to form the heavy chain T-h (29,500) and the light chain T-L (6,500) of active thrombin. In the presence of antithrombin, an additional prothrombin conversion pathway is observed in which the zymogen is directly cleaved to form P-3 and F-A + B (30,000) prior to thrombin generation. Trace amounts of free thrombin remain uninhibited by antithrombin and could bias the zymogen activation pathway. Hirudin is known to neutralized thrombin instantaneoulsly. We demonstrate that the purified leech protein also binds to P-3 and prevents thrombin formation. When hirudin is added to activation mixtures at concentrations sufficient to virtually suppress P-3 conversion to thrombin, molecular species from both activation pathways are observed. Thus two human prothrombin conversion sequences appear to be initiated by Factor X-3 and may be of physiological significance.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1112820

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Generation of the combined prothrombin activation peptide (F1-2) during the clotting of blood and plasma.

Authors:  D L Aronson; L Stevan; A P Ball; B R Franza; J S Finlayson
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

2.  Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.

Authors:  H A Liebman; S A Limentani; B C Furie; B Furie
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

3.  Blood coagulation factor X mRNA encodes a single polypeptide chain containing a prepro leader sequence.

Authors:  M R Fung; R M Campbell; R T MacGillivray
Journal:  Nucleic Acids Res       Date:  1984-06-11       Impact factor: 16.971

4.  Novel 2-aminobenzamides as potential orally active antithrombotic agents.

Authors:  Amit Verma; Rajani Giridhar; Ashish Kanhed; Anshuman Sinha; Pratik Modh; Mange R Yadav
Journal:  ACS Med Chem Lett       Date:  2012-10-31       Impact factor: 4.345

5.  Fibrinogen-fibrin conversion. The mechanism of fibrin-polymer formation in solution.

Authors:  G F Smith
Journal:  Biochem J       Date:  1980-01-01       Impact factor: 3.857

6.  Comparison of amino acid sequence of bovine coagulation Factor IX (Christmas Factor) with that of other vitamin K-dependent plasma proteins.

Authors:  K Katayama; L H Ericsson; D L Enfield; K A Walsh; H Neurath; E W Davie; K Titani
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

7.  Human coagluation factor V purification and thrombin-catalyzed activation.

Authors:  B Dahlbäck
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

8.  Relationship between platelet secretion and prothrombin cleavage in native whole blood.

Authors:  M E Rybak; H K Lau; B Tomkins; R D Rosenberg; R I Handin
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

9.  Detection of protein C activation in humans.

Authors:  K A Bauer; B L Kass; D L Beeler; R D Rosenberg
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

10.  The measurement of thrombin in clotting blood by radioimmunoassay.

Authors:  M A Shuman; P W Majerus
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.